Compare Quest Diagnostics Inc (DGX) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Fortinet Inc — how do they compare? Quest Diagnostics Inc trades at $237.53 (market cap $26.21B), while Fortinet Inc trades at $161.35 (market cap $118.78B). The key difference: Fortinet Inc is far larger — about 4.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals.
| DGX | FTNT | |
|---|---|---|
Market Cap | $26.21B | $118.78B |
Sector | Health | Technology |
52-Week High | $238.50 | $168.29 |
52-Week Low | $173.49 | $75.23 |
Enterprise Value | $31.97B | $115.21B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Fortinet (FTNT) trades at $164.09, down slightly by 0.07% today, with strong technical momentum showing bullish moving average signals. The company demonstrates robust fundamentals with revenue growing from $6.0B in 2024 to $6.8B in 2025 and net income reaching $1.85B. Recent Q2 2026 earnings beat expectations with $0.90 EPS versus $0.746 expected, continuing a pattern of strong quarterly performance. Analyst consensus remains positive with a $174.50 price target representing 6% upside potential from current levels.
Fortinet presents a compelling growth story with cybersecurity demand accelerating amid AI adoption, though elevated valuation metrics (P/E 57.2, P/S 16.08) require continued execution. Key risks include competitive pressures in the cybersecurity space and the stock's premium pricing relative to historical norms. The combination of strong earnings momentum, institutional support, and positive industry trends supports a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
